{"result": {"id": "26001ce2-25e2-4ddf-a644-97ba4dce590d", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>SGLT2I<|>ORGANIZATION<|>SGLT2i is a class of medications that inhibit sodium-glucose cotransporter-2, showing cardiorenal benefits in CKD patients with/without diabetes\")\n##\n(\"entity\"<|>CKD<|>ORGANIZATION<|>Chronic Kidney Disease, a condition requiring combined antihypertensive therapy and SGLT2i consideration when eGFR ≥20mL/(min·1.73m²)\")\n##\n(\"entity\"<|>ESRD<|>ORGANIZATION<|>End-Stage Renal Disease requiring dialysis, with specific blood pressure management challenges related to volume status\")\n##\n(\"entity\"<|>ACEI<|>ORGANIZATION<|>Angiotensin-converting enzyme inhibitors, first-line therapy for hypertension in diabetes patients\")\n##\n(\"entity\"<|>ARB<|>ORGANIZATION<|>Angiotensin receptor blockers, alternative first-line therapy for hypertension in diabetes patients\")\n##\n(\"entity\"<|>GLP-1RA<|>ORGANIZATION<|>Glucagon-like peptide-1 receptor agonists, recommended for diabetes patients to reduce cardiorenal risks\")\n##\n(\"entity\"<|>2型糖尿病<|>ORGANIZATION<|>Type 2 diabetes mellitus, frequently comorbid with hypertension (60% in China) increasing cardiovascular risks\")\n##\n(\"relationship\"<|>SGLT2I<|>CKD<|>SGLT2i provides renal protection in CKD patients when eGFR ≥20mL/(min·1.73m²)<|>9)\n##\n(\"relationship\"<|>ACEI<|>ARB<|>Both are first-line antihypertensives for diabetes patients, often used interchangeably<|>8)\n##\n(\"relationship\"<|>GLP-1RA<|>2型糖尿病<|>GLP-1RA reduces cardiorenal risks in type 2 diabetes patients<|>8)\n##\n(\"relationship\"<|>CKD<|>ESRD<|>ESRD represents the most advanced stage of CKD progression<|>7)\n##\n(\"relationship\"<|>SGLT2I<|>2型糖尿病<|>SGLT2i benefits type 2 diabetes patients with CKD<|>7)\n##\n(\"relationship\"<|>ACEI<|>2型糖尿病<|>ACEI are foundational therapy for hypertension in diabetes<|>8)\n##\n(\"relationship\"<|>ARB<|>2型糖尿病<|>ARB are foundational therapy for hypertension in diabetes<|>8)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558764, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 563, "prompt_tokens": 3029, "total_tokens": 3592, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 2944}, "prompt_cache_hit_tokens": 2944, "prompt_cache_miss_tokens": 85}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: SGLT2i在已完成的研究中 ,对无论是否 合并 2型糖尿病的 CKD患者均展现出了心肾保护作 用 ,并 在 研 究 中 对 血 压 有 一 定 改 善 作 用[396] 。 如 果 eGFR≥20mL/(min · 1.73 m2) ,则建议糖尿病和非 糖尿病肾病的 CKD患者使用 SGLT2i。\n　　　多数 CKD 患者需要联合治疗以达到血压目标  值 。 目前缺乏针对 CKD患者预后开展的不同降压药  联合方案的比较研究 。建议根据患者年龄、合并症等  具体情况进行药物联合选择 。必要时也可联合使用 α 受体阻滞剂、中枢降压药等治疗。\n　8.6.3  ESRD透析患者的降压治疗    目前就血液透 析人群高血压的诊断及血压控制标准均缺乏充分的研 究证据[395] 。我国目前临床采用的为透析前诊室收缩 压<160mmHg[596] 。影响血液透析患者血压控制的 因素众多 ,容量过负荷是重要因素 。在血液透析患者 的血压管理中 ,应重视对容量的管理 ,使患者尽可能达 到干体重 。 同时 ,降压药的种类 ,应用时机及剂量均需 考虑透析操作过程中血流动力学的变化以及对药物清 除的影响进行相应调整。\n　　　同样 ,腹膜透析患者血压控制目标目前亦无充分  研究证据 。我国参考国际腹膜透析协会指南建议 ,建  议腹膜透析患者的血压控制目标为<140/90mmHg。 容 量 管 理 对 腹 膜 透 析 患 者 的 血 压 管 理 也 同 样  关键[597-598] 。\n\n\n\n8.7   高血压合并糖尿病\n\n要点 8G   高血压合并糖尿病\n　　　· 糖 尿 病 患 者 的 血 压 控 制 目 标 为 < 130/ 80mmHg( Ⅱa,B) 。老年或伴严重冠心病的糖尿病  患者 ,可放宽至 140/90mmHg(Ⅱ a, B) 。合并糖尿  病的孕妇 , 建议 血 压 控 制 目 标 为 ≤135/85 mmHg ( Ⅱa,B) 。\n　　　· 常用降压药均可用于糖尿病合并高血压的治 疗 ;联合使用降压药时 ,应该以 ACEI或 ARB为基础 ( Ⅰ ,A) 。\n　　　·推荐高血压合并糖尿病患者使用 SGLT2i和 GLP-1RA以降低心肾事件风险 , 同时具有一定降压 作用( Ⅰ ,A) 。\n\n　　　我国 2 型糖尿病患者中约 60%合并高血压[599] 。 糖尿病合并高血压可使患者心脑血管事件的风险显著  增加[600] 。降压治疗能显著降低糖尿病患者大血管事  件和死亡风险\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>SGLT2I<|>ORGANIZATION<|>SGLT2i is a class of drugs that have shown cardiorenal protective effects in patients with CKD, regardless of whether they have type 2 diabetes, and also have a certain effect on improving blood pressure.\")\n##\n(\"entity\"<|>CKD<|>ORGANIZATION<|>Chronic Kidney Disease (CKD) is a condition where patients often require combined therapy to achieve blood pressure targets, and there is a lack of comparative studies on different antihypertensive drug combination regimens for CKD patients.\")\n##\n(\"entity\"<|>ESRD<|>ORGANIZATION<|>End-Stage Renal Disease (ESRD) is a condition where patients undergoing dialysis face challenges in blood pressure management, with factors like volume overload being significant.\")\n##\n(\"entity\"<|>ACEI<|>ORGANIZATION<|>ACEI is a class of drugs recommended as a base for combined antihypertensive therapy in patients with diabetes and hypertension.\")\n##\n(\"entity\"<|>ARB<|>ORGANIZATION<|>ARB is a class of drugs recommended as a base for combined antihypertensive therapy in patients with diabetes and hypertension.\")\n##\n(\"entity\"<|>GLP-1RA<|>ORGANIZATION<|>GLP-1RA is a class of drugs recommended for use in hypertensive patients with diabetes to reduce cardiorenal event risks and has a certain antihypertensive effect.\")\n##\n(\"entity\"<|>2型糖尿病<|>ORGANIZATION<|>Type 2 diabetes is a condition where about 60% of patients in China also have hypertension, and the combination significantly increases the risk of cardiovascular events.\")\n##\n(\"relationship\"<|>SGLT2I<|>CKD<|>SGLT2i is recommended for use in CKD patients with or without diabetes to provide cardiorenal protection and improve blood pressure.<|>8)\n##\n(\"relationship\"<|>ACEI<|>ARB<|>Both ACEI and ARB are recommended as base drugs for combined antihypertensive therapy in patients with diabetes and hypertension.<|>7)\n##\n(\"relationship\"<|>GLP-1RA<|>2型糖尿病<|>GLP-1RA is recommended for hypertensive patients with diabetes to reduce cardiorenal event risks.<|>7)\n##\n(\"relationship\"<|>CKD<|>ESRD<|>CKD can progress to ESRD, which requires dialysis and has specific challenges in blood pressure management.<|>6)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_704a3403e09433430960585cd1a38090c00ab917dc60addb45ebae10c9c13a5a_v2"}